Cargando…

Effects of the Edaravone, a Drug Approved for the Treatment of Amyotrophic Lateral Sclerosis, on Mitochondrial Function and Neuroprotection

Edaravone, the first known free radical scavenger, has demonstrated cellular protective properties in animals and humans. Owing to its antioxidant activity, edaravone modulates oxidative damage in various diseases, especially neurodegenerative diseases. In 2015, edaravone was approved in Japan to tr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cha, Sun Joo, Kim, Kiyoung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8868074/ https://www.ncbi.nlm.nih.gov/pubmed/35204078 http://dx.doi.org/10.3390/antiox11020195

Ejemplares similares

Renal function in amyotrophic lateral sclerosis patients on long-term treatment with edaravone
por: Kakimoto, Asako, et al.
Publicado: (2021)

Role of Edaravone as a Treatment Option for Patients with Amyotrophic Lateral Sclerosis
por: Cho, HaEun, et al.
Publicado: (2020)

Effect of edaravone therapy in Korean amyotrophic lateral sclerosis (ALS) patients
por: Park, Jin-Mo, et al.
Publicado: (2019)

Ethnical Disparities in Response to Edaravone in Patients With Amyotrophic Lateral Sclerosis
por: Jayasinghe, Maleesha, et al.
Publicado: (2022)

Long-term effects of edaravone on survival of patients with amyotrophic lateral sclerosis
por: Okada, Masamitsu, et al.
Publicado: (2018)

Clinical staging in amyotrophic lateral sclerosis: analysis of Edaravone Study 19
por: Al-Chalabi, Ammar, et al.
Publicado: (2021)

Serum uric acid level predicts the progression of amyotrophic lateral sclerosis following treatment with edaravone
por: Han, Hee Jo, et al.
Publicado: (2022)

How is edaravone effective against acute ischemic stroke and amyotrophic lateral sclerosis?
por: Watanabe, Kazutoshi, et al.
Publicado: (2018)

Recent Advances on the Role of GSK3β in the Pathogenesis of Amyotrophic Lateral Sclerosis
por: Choi, Hyun-Jun, et al.
Publicado: (2020)

Magnetic resonance metrics to evaluate the effect of therapy in amyotrophic lateral sclerosis: the experience with edaravone
por: Distaso, Eugenio, et al.
Publicado: (2021)

Assessment of Therapeutic Response of Edaravone and Riluzole Combination Therapy in Amyotrophic Lateral Sclerosis Patients
por: Samadhiya, Swapnil, et al.
Publicado: (2022)

Investigating Edaravone Use for Management of Amyotrophic Lateral Sclerosis (ALS): A Narrative Review
por: Neupane, Purushottam, et al.
Publicado: (2023)

Glutathione S-Transferase Rescues Motor Neuronal Toxicity in Fly Model of Amyotrophic Lateral Sclerosis
por: Cha, Sun Joo, et al.
Publicado: (2020)

Post-Marketing Experience of Edaravone in Amyotrophic Lateral Sclerosis: A Clinical Perspective and Comparison With the Clinical Trials of the Drug
por: Ortiz, Juan Fernando, et al.
Publicado: (2020)

Assessment of Use and Safety of Edaravone for Amyotrophic Lateral Sclerosis in the Veterans Affairs Health Care System
por: Vu, Michelle, et al.
Publicado: (2020)

Safety and efficacy of edaravone in patients with amyotrophic lateral sclerosis: a systematic review and meta-analysis
por: Nourelden, Anas Zakarya, et al.
Publicado: (2023)

Long-term outcomes of edaravone in amyotrophic lateral sclerosis in South Korea: 72-week observational study
por: Park, Jin-Mo, et al.
Publicado: (2022)

Radicava/Edaravone Findings in Biomarkers From Amyotrophic Lateral Sclerosis (REFINE-ALS): Protocol and Study Design
por: Berry, James, et al.
Publicado: (2021)

Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment
por: Genge, Angela, et al.
Publicado: (2022)

In silico studies reveal structural deviations of mutant profilin-1 and interaction with riluzole and edaravone in amyotrophic lateral sclerosis
por: Sadr, Ahmad Shahir, et al.
Publicado: (2021)

The neuroprotective effects of human growth hormone as a potential treatment for amyotrophic lateral sclerosis
por: Chung, Jin-Young, et al.
Publicado: (2015)

Long‐term edaravone efficacy in amyotrophic lateral sclerosis: Post‐hoc analyses of Study 19 (MCI186‐19)
por: Shefner, Jeremy, et al.
Publicado: (2019)

Mechanisms of Neuroprotection by Protein Disulphide Isomerase in Amyotrophic Lateral Sclerosis
por: Walker, Adam K., et al.
Publicado: (2011)

The potential of GPNMB as novel neuroprotective factor in amyotrophic lateral sclerosis
por: Tanaka, Hirotaka, et al.
Publicado: (2012)

Autologous bone marrow mononuclear cells as neuroprotective treatment of amyotrophic lateral sclerosis
por: Ruiz-López, Francisco José, et al.
Publicado: (2016)

Glutathione in the Nervous System as a Potential Therapeutic Target to Control the Development and Progression of Amyotrophic Lateral Sclerosis
por: Kim, Kiyoung
Publicado: (2021)

Safety and efficacy of edaravone in well-defined Iranian patients with amyotrophic lateral sclerosis: A parallel-group single-blind trial
por: Eishi-Oskouei, Alireza, et al.
Publicado: (2021)

Improved Long-Term Survival with Edaravone Therapy in Patients with Amyotrophic Lateral Sclerosis: A Retrospective Single-Center Study in Japan
por: Houzen, Hideki, et al.
Publicado: (2021)

Mitochondrial dynamic abnormalities in amyotrophic lateral sclerosis
por: Jiang, Zhen, et al.
Publicado: (2015)

Mitochondrial dynamism and the pathogenesis of Amyotrophic Lateral Sclerosis
por: Cozzolino, Mauro, et al.
Publicado: (2015)

The Impact of Mitochondrial Dysfunction in Amyotrophic Lateral Sclerosis
por: Zhao, Jiantao, et al.
Publicado: (2022)

Could Conservative Iron Chelation Lead to Neuroprotection in Amyotrophic Lateral Sclerosis?
por: Moreau, Caroline, et al.
Publicado: (2018)

Retromer stabilization results in neuroprotection in a model of Amyotrophic Lateral Sclerosis
por: Muzio, Luca, et al.
Publicado: (2020)

Neuroprotective effects of violacein in a model of inherited amyotrophic lateral sclerosis
por: Olivera-Bravo, Silvia, et al.
Publicado: (2022)

Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients
por: Abe, Koji, et al.
Publicado: (2014)

Monocarboxylate transporter functions and neuroprotective effects of valproic acid in experimental models of amyotrophic lateral sclerosis
por: Gyawali, Asmita, et al.
Publicado: (2022)

Mitochondrial Transport and Turnover in the Pathogenesis of Amyotrophic Lateral Sclerosis
por: Granatiero, Veronica, et al.
Publicado: (2019)

Amyotrophic Lateral Sclerosis and Agricultural Environments: A Systematic Review
por: Kang, Hyun, et al.
Publicado: (2014)

Novel Neuroprotective Multicomponent Therapy for Amyotrophic Lateral Sclerosis Designed by Networked Systems
por: Herrando-Grabulosa, Mireia, et al.
Publicado: (2016)

Slowing the loss of physical function in amyotrophic lateral sclerosis with edaravone: Post hoc analysis of ALSFRS‐R item scores in pivotal study MCI186‐19
por: Brooks, Benjamin Rix, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9k5ki6ov0qtfggrm6pvmruc1fm